Results 111 to 120 of about 31,625 (291)

The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time‐driven activity‐based costing study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Patients with myelodysplastic syndromes (MDS) often require red blood cell (RBC) transfusion. However, the true cost of RBC transfusion, beyond the acquisition cost of the unit, is poorly defined. We conducted a prospective time‐driven activity‐based costing study at a large Australian university teaching hospital.
Allison Mo   +15 more
wiley   +1 more source

Incidence and Analysis of 7 Years Adverse Transfusion Reaction: A Retrospective Analysis. [PDF]

open access: yesIndian J Hematol Blood Transfus, 2020
Saha S, Krishna D, Prasath R, Sachan D.
europepmc   +1 more source

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

open access: yesBritish Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall   +14 more
wiley   +1 more source

Methaemoglobinaemia: From pathophysiology to contemporary clinical management

open access: yesBritish Journal of Haematology, EarlyView.
Summary Methaemoglobin (MetHb) is an oxidised form of haemoglobin (Hb) unable to bind oxygen. Raised levels of MetHb reduce the blood's oxygen‐carrying capacity, causing potentially severe hypoxaemia and possible death. The condition arises from three main pathologies: mutations in globin genes causing Haemoglobin‐M, inherited deficiency of the enzyme ...
Alexander J. Twine, David C. Rees
wiley   +1 more source

Investigation on the current status of blood safety surveillance and management in blood collection and supply institutions in Sichuan, China

open access: yesZhongguo shuxue zazhi
[Objective] Blood safety surveillance is a critical measure for the objective assessment of blood quality and enhancing transfusion safety. This study aims to comprehensively understand the current status of blood safety surveillance and management in ...
LI Meng   +6 more
doaj   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

open access: yesHaemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita   +2 more
wiley   +1 more source

The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease

open access: yes, 2015
International audienceBackground: Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an immune response to transfused red blood cells (RBCs).
Bartolucci, P.   +10 more
core   +1 more source

A Study on Acute Adverse Effects of Blood Transfusion in a Tertiary Care Centre [PDF]

open access: yes, 2020
OBJECTIVE: This study was designed to analyse the frequency of acute transfusion reactions and nature of transfusion reactions reported to the blood bank in the kilpauk medical college and hospital and the Department of Transfusion Medicine, Tamilnadu ...
Vijayakumar, P
core  

Blood Transfusion Reactions in Elderly Patients Hospitalized in a Multilevel Geriatric Hospital

open access: yesJournal of Aging Research, 2014
Background/Objectives. Blood transfusion is a critical issue for patients with chronic diseases such as heart failure, chronic kidney disease, and malignancy. However, side effects are not rare.
E. Lubart   +4 more
doaj   +1 more source

Gene Editing for Haemophilia—The Next Frontier

open access: yesHaemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy